Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem

Dapagliflozin cuts HbA1c in paediatric T2D
Dapagliflozin reduced HbA1c by 1.03 percentage points more than placebo in children and adolescents with type 2 diabetes (T2D), while saxagliptin showed no significant reduction vs placebo in the phase III T2NOW trial presented at EASD 2023.

First-line therapies for advanced NSCLC improve survival, QoL
Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.

Behavioural interventions improve screening colonoscopy uptake
Use of behavioural interventions, specifically multicomponent and patient navigation interventions, helps increase the uptake of colonoscopy for colorectal cancer (CRC) screening, reveals a study.

Finerenone confers cardiorenal benefits in Chinese CKD, T2D patients
In the subgroup analysis of the phase III FIGARO-DKD trial, the selective nonsteroidal mineralocorticoid receptor antagonist finerenone conferred cardiorenal benefits in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The findings were consistent with that observed in the overall cohort.





